Latest Breaking News On - Danny bar zohar - Page 6 : comparemela.com

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

United statesUnited kingdomBrauti fritzenMerck pressHead of global developmentMyasthenia gravisNeuromyelitis optica spectrum disorderMultiple sclerosisChord therapeuticsDanny bar zoharGlobal developmentOmega fundsMerck press releasesMedia contactScience and technologyChord therapeutics

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO®

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releasesMedia contactRal met inhibitor

Merck: TEPMETKO (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

TEPMETKO is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harboring alterations leading to METex14 skipping Not intended

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releases

Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United statesJoern peter halleMerck kgaGlobal head of development for the healthcareGlobal head of research for the healthcareMerck kgaaGroup websiteDanny bar zoharGlobal headApoptosis proteinsNektar therapeutic

Merck: New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Phase II post-hoc data show evobrutinib reduced acute and chronic inflammation processes in the central nervous system that may be early indicators of MS disease progression Additional data

United statesUnited kingdomComunidad autonoma de catalunaBrauti fritzenXavier montalbanHebron university hospitalMerck pressNeuroimmunology department neurorehabilitation unitSclerosis centre of catalonia cemcatGlobal head of development for the healthcareResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisMultiple sclerosis centreDanny bar zohar